Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Angal, lozenges [menthol],
Angal, lozenges · 1 trial · 1 indication
TSS (Tonsillopharyngitis Severity Score) is a questionnaire for evaluation of the five following symptoms severity: pharyngalgia, difficulty in swallowing, salivation, hyperemia of pharyngeal mucosa, and body temperature increase according to a 4-point scale: 0 : no symptoms 1. : insignificant symptom 2. : moderate symptom 3. : significant symptom fever 0 pts : \<37.5 °С; 1. pts : 37.5 to \<38.5 °С; 2. pts : 38.5 to \<39.5 °С; 3. pts : ≥ 39.5 °С. TSS total ranges are 0-15.
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if this will happen earlier than 4th day of treatment. |
| Arm B | ACTIVE_COMPARATOR | ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if this will happen earlier than 5th day of treatment. |
| Name | Type | Description |
|---|---|---|
| Angal, lozenges [menthol], | DRUG | Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution. |
| ANTI-ANGIN® FORMULA | DRUG | 0,2 mg + 2 mg + 50 mg (LLC "Valeant", Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution. |
Inclusion Criteria: * Voluntarily signed informed consent for participation in this clinical study; 18 to 45 years old inclusive, male and female; * Diagnosed uncomplicated acute infectious and inflammatory diseases of the pharynx, accompanied by a sore throat; * Onset of first symptoms of the unco...
Angal, lozenges is used for the treatment of sore throat. It is a small molecule medicine in the ear, nose and throat therapeutic area, developed by Novartis AG. The product is a lozenge formulation, and the menthol version is referred to as Angal, lozenges [menthol].
Angal, lozenges is developed by Novartis AG, which trades under the ticker NVS. Novartis is the company behind the Angal lozenge product, including the menthol variant, Angal, lozenges [menthol], studied for sore throat.
Angal, lozenges has reached Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The program is investigational and remains in clinical development for sore throat.
Angal, lozenges has been studied in one completed Phase 3 trial, NCT03095521. That trial compared Angal, lozenges [menthol] with ANTI-ANGIN FORMULA lozenges in patients with a sore throat. It enrolled 228 participants in Russia, was randomized, actively controlled, and included adults aged 18 years and older.
Angal, lozenges [menthol] is the menthol variant of Angal, lozenges. The two names refer to the same lozenge product line developed by Novartis AG for sore throat, and the menthol version was the formulation evaluated in the completed Phase 3 trial NCT03095521.